GOLDENWELL BIOTECH, INC. (GWLL) stock: key figures, P/E, revenue and dividend
Consumer Staples · United States · ISIN US38138N1046
GOLDENWELL BIOTECH, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 55.00 USD |
| Gross profit | 12.00 USD |
| Operating income | -113,326.00 USD |
| EBIT | -288,071.00 USD |
| Net income | -296,471.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Solon, Ohio.
More stocks
- Taiwan Ostor (8080.TWO)
- Wspierania Przedsiebiorczosci (PTW.WA)
- BROADWIND, INC. (BWEN)
- Freeman Gold Corp (FMAN.V)
- Inzi Controls (023800.KS)
- Optex Systems Holdings Inc (OPXS)
- Trans-Sun Materials Technology Company Limited (6967.TWO)
- Globus Maritime Ltd (GLBS)
- Top High Image (3284.TWO)
- REGIS CORP (RGS)
- Netbay Public Company Limited (NETBAY.BK)
- Kapsch Traffic (KTCG.VI)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.